Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
about
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized miceTwo potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformationsA novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaWhat Taiwan contributes to the world of allergy and clinical immunology?Skewed Exposure to Environmental Antigens Complements Hygiene Hypothesis in Explaining the Rise of AllergyNovel diagnostic approaches and biological therapeutics for intrinsic asthma.Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.The IgE gene in primates exhibits extraordinary evolutionary diversity.Update on optimal use of omalizumab in management of asthma.Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.Chinese herbal extracts of Rubia cordifolia and Dianthus superbus suppress IgE production and prevent peanut-induced anaphylaxisSerum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by OmalizumabStructural and Physical Basis for Anti-IgE Therapy.Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.Latex allergy: a model for therapy.Omalizumab in the treatment of severe asthma: efficacy and current problems.Structure and function of immunoglobulinsImmunoglobulin E receptor signaling and asthmaPotential applications of designed ankyrin repeat proteins in diagnostics and therapeutics.Changing patterns of antigen exposure and their impact on the prevalence of allergy.Anaphylactic shock ensuing therapeutic puncture of an echinococcal cyst.Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.New and Emerging Targeted Systemic Therapies: A New Era for Atopic Dermatitis.From IgE to Omalizumab.Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Cytomegalic hepatitis in a patient receiving omalizumab.Severe asthma and the omalizumab option.IgE receptor-mediated mast-cell renin releaseA high-affinity monoclonal anti-IgE antibody for depletion of IgE and IgE-bearing cells.Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.Novel therapies for severe asthma in children and adults.Oral immunotherapy for food allergy.Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.Variability of total and free IgE levels and IgE receptor expression in allergic subjects in and out of pollen season.Attention deficit-hyperactivity disorder is associated with allergic symptoms and low levels of hemoglobin and serotonin
P2860
Q24604440-E5513870-4285-4C3F-8B57-897A056A4543Q27688964-FCC0FCC1-4F63-44DB-A450-2851CF1512B2Q27689386-EEC0BBE1-D179-4BA3-915B-9A367BD376CDQ28661627-1E6D9E32-4DFB-48A9-B4CF-48C9640A7759Q33639328-EDA2935A-AE0A-4F1A-912F-C7558FC2A698Q33904534-4CFCCDB5-4C04-4741-BCF7-66DD5FD85193Q33966937-13CAEDC0-86D0-45C6-BE87-7CB0DFE8B01FQ34070321-3803FDB6-5CB3-4266-9736-1A410450602DQ35117827-F26DE23F-AD61-4151-9D4E-8BADC743432AQ35183644-CBEA1D2F-D77C-4E73-A054-46C2CF294154Q35477889-72D2FCEF-9C4F-4A07-B8C2-8FD810DD54D1Q35762396-605DBE53-0B20-446C-B984-3D2B867E501BQ35783662-CB53CB0A-D560-40D7-BE10-AC25444AE591Q36870059-7CBD4155-0719-4FBC-A430-9A80AB09E984Q37161497-D9A94C29-5EF0-46B7-9A1F-538535CB35DEQ37171082-DBA3908A-61FD-4B53-91BC-4C8BD8A400CEQ37362658-AAC0AE17-D007-461A-B52B-C9CA7D934985Q37696721-7E37BA6B-70AE-4AC7-B608-4081A2212A20Q37907670-6332E850-0F11-43FD-8AA9-90F69D7E7E75Q38089263-7838E2FE-7C4F-45A9-8F9B-732ECF766A11Q38265966-8EF0D881-182E-4946-8F80-A0E33AF1DCB4Q38302952-268DFA62-2BB0-4244-85EF-29E9A0C3A532Q38396322-5DFF4F45-C0E0-4FFA-8293-4208CECBBE0BQ38602326-38399ACB-BDE4-4D8D-80FE-BEA4339CF873Q38793428-2D7C8518-A8B5-4A50-B3F7-60E3E0B4D429Q38811111-D6104E3B-EFAE-415E-B6E2-D93EC6CC696BQ38982481-42EBDE09-17D0-4394-82E9-1C02AFB6BF88Q40555356-0C0A7A34-96AD-406C-ACBF-5D2F3B1331C3Q40740336-9C4FF16D-27B4-45D8-BAC7-F5997C666F8FQ41899457-68F5F473-B30A-40D8-AAA5-D8A10E3EE647Q46715031-558AE361-84A9-4752-80E2-3B167D898496Q48498634-A4D71451-E4FE-4BC7-A79C-2383225498C9Q52668271-04161281-16A1-4F86-B8C8-36A4C17BC4D3Q52757118-BAEEB501-7957-4BFA-AD3E-F3340FDCFC5FQ52976551-5E89F37C-6EAB-472C-B757-99394B16799CQ53628624-98C6A12C-37C8-4BE8-8984-DAAFB2EC8CA8Q56515589-52981051-A772-4D2E-A5FC-50BC4A38C15C
P2860
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@ast
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@en
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@nl
type
label
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@ast
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@en
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@nl
prefLabel
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@ast
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@en
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@nl
P2093
P3181
P1476
Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases
@en
P2093
Alfur F Hung
C Long Hsu
Pheidias C Wu
Tse Wen Chang
P304
P3181
P356
10.1016/S0065-2776(06)93002-8
P407
P577
2007-01-01T00:00:00Z